Compugen Ltd. announced that the first patient has been dosed in the combination expansion cohort of its ongoing Phase 1 clinical trial evaluating COM701, Compugen's first-in-class anti-PVRIG antibody, in combination with Opdivo® (nivolumab). The indications for the combination therapy expansion cohort, ovarian, breast, endometrial and colorectal cancers were selected based on preclinical biomarker assessments. The Phase 1b combination cohort expansion study is part of the Phase 1 open-label clinical trial designed to assess the safety, tolerability and preliminary anti-tumor clinical activity of administering escalating doses of COM701 monotherapy, as well as in combination with Bristol-Myers Squibb's Opdivo® in patients with advanced solid tumors. The Phase 1b combination cohort expansion arm is currently recruiting patients in the United States.